Negative Enrichment of Circulating Tumor Cells in Blood Using a Microfluidic Chip

  • Hamizah A. CognartEmail author
  • Chia-Pin Chang
Part of the Methods in Molecular Biology book series (MIMB, volume 1547)


The enumeration and analysis of circulating tumor cells (CTCs) is an increasing interest for monitoring disease progression or response to treatment, specifically as a companion diagnostic for new anticancer drugs, and for research into the mechanisms of disease progression and metastases. Ideally, CTCs would be enriched from very small samples, with minimal handling, high recovery, and no requirement for the expression of specific surface markers. Here, we describe negative enrichment as the preferred approach for cancer cell isolation using a microfluidic platform.

Key words

Circulating tumor cells (CTCs) Cancer cell isolation Metastasis Negative enrichment White blood cell (WBC) depletion Microfluidic 



This work was supported by the Science and Engineering Research Council of A*STAR (Agency for Science, Technology and Research), Singapore under the grant number 1031490005.


  1. 1.
    Racila E, Euhus D, Weiss AJ et al (1998) Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 95:4589–4594CrossRefGoogle Scholar
  2. 2.
    Cristofanilli M, Budd G (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Engl J Med 351:781–791CrossRefGoogle Scholar
  3. 3.
    De Bono JS, Scher HI, Montgomery RB et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309CrossRefGoogle Scholar
  4. 4.
    Cohen SJ, Punt CJ, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221CrossRefGoogle Scholar
  5. 5.
    Hiltermann TJN, Pore MM, Van Den Berg A et al (2005) Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol 23:2937–2942CrossRefGoogle Scholar
  6. 6.
    Krebs MG, Sloane R, Priest L et al (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29:1556–1563CrossRefGoogle Scholar
  7. 7.
    Matsusaka S, Chin K, Oqura M et al (2010) Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci 101:1067–1071CrossRefGoogle Scholar
  8. 8.
    Rao C, Bui T, Connelly M et al (2011) Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol 38:755–760CrossRefGoogle Scholar
  9. 9.
    Gazzaniga P, Gradilone A, De Berardinis E et al (2012) Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a cellsearch analysis. Ann Oncol 23:2352–2356CrossRefGoogle Scholar
  10. 10.
    Allard WJ, Matera J, Miller MC et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904CrossRefGoogle Scholar
  11. 11.
    Coumans FAW, Ligthart ST, Uhr JW et al (2012) Challenges in the Enumeration and Phenotyping of CTC. Clin Cancer Res 18:5711–5718CrossRefGoogle Scholar
  12. 12.
    Sajay BG, Chang CP, Ahmad H et al (2013) Towards an optimal and unbiased approach for tumor cell isolation. Biomed Microdevices 15:699–709CrossRefGoogle Scholar
  13. 13.
    Sajay BG, Chang CP, Ahmad H et al (2014) Microfluidic platform for negative enrichment of circulating tumor cells. Biomed Microdevices 16:537–548CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Institut Curie, PSL Research UniversityParisFrance
  2. 2.Sorbonne UniversitésParisFrance
  3. 3.BioElectronics ProgrammeInstitute of Microelectronics, A*STAR (Agency for Science, Technology and Research)SingaporeSingapore

Personalised recommendations